Orthopediatrics Corp. has announced its preliminary unaudited financial highlights for the third quarter ended September 30, 2025, and revised 2025 financial guidance. In the third quarter of 2025, the company helped over 37,100 children, bringing the total number of children helped since inception to approximately 1.3 million.
The preliminary unaudited net revenue for the third quarter of 2025 was approximately $61.2 million, representing a 12% growth compared to the same period in 2024. Domestic net revenue for the third quarter is expected to be approximately $48.7 million, reflecting a 14% growth, while international net revenue is expected to be approximately $12.5 million, showing a 6% growth. Excluding 7D capital sales, the net revenue for the third quarter of 2025 was approximately $60.7 million, indicating a 17% growth compared to the third quarter of 2024.
The company also revised its 2025 financial guidance, now expecting revenue of $233.5 million to $234.5 million, which is a decrease from the previous guidance range of $237.0 million to $242.0 million. This represents a growth of 14% to 15% over 2024 revenue. The company reaffirmed its expectation for annual set deployment to be $15.0 million and the adjusted EBITDA guidance range of $15.0 million to $17.0 million for the full year of 2025.
David Bailey, President & CEO of Orthopediatrics, noted that in the third quarter, the company faced headwinds driven by delayed 7D capital sales and challenges within the Latin and South America segment of the business, resulting in a revenue shortfall relative to expectations. Bailey also mentioned the uncertainty in the timing of 7D capital sales and Latin and South America set sales and stocking orders, which led to the revision of the 2025 guidance range.
The company is committed to driving revenue growth to expand profitability and support achieving cash flow break-even in 2026. Orthopediatrics aims to continue helping more children every year, leveraging its comprehensive product portfolio and commercial footprint in pediatric orthopedics.
The preliminary unaudited net revenue estimates for 2025 are subject to adjustment pending the completion of review and audit procedures by the company’s independent registered public accounting firm.
Orthopediatrics will host a conference call on October 9, 2025, to discuss the preliminary results and plans to release its full third quarter 2025 financial results after market close on October 28, 2025. Following these announcements, the company's shares moved -0.83%, and are now trading at a price of $17.95. Check out the company's full 8-K submission here.
